CDK6

Overview

CDK6 (Cyclin-dependent kinase 6) is a member of the cyclin-dependent kinase family, which plays a crucial role in cell cycle progression by phosphorylating and inactivating the retinoblastoma protein (pRb). Alterations in CDK6, such as amplification, lead to constitutive activation of the cell cycle and are frequently observed in various cancers, including glioblastoma.

Alterations observed in the corpus

  • Amplification/Alteration: Observed in 1% of glioblastoma samples as part of the core RB pathway alterations PMID:18772890.
  • Identified as mutated in LUAD (TSP, n=188); cell cycle pathway member co-altered with CDK4, CCND1, CCNE1, and CDKN2A/B. PMID:18948947
  • Amplified/mutated in TCGA lung squamous cell carcinoma cohort (178 tumors) PMID:22960745
  • Frequently focally amplified in esophageal adenocarcinoma (EAC), contributing to cell-cycle deregulation PMID:23525077
  • Recurrent focal amplification in GBM; contributes to Rb-pathway dysregulation (overall 78.9% of GBM) PMID:24120142
  • Co-targeted with CDK4 by dalpiciclib in NPC; combination + camrelizumab achieved ORR 32.4% in PD-1-refractory R/M NPC PMID:24952746
  • Recurrent focal amplification in CIN gastric adenocarcinoma; co-amplified with CCNE1 and CCND1; suggests CDK4/6 inhibitor evaluation in CIN-subtype tumours PMID:25079317
  • Amplification identified in Pt2 of a multi-region WGS gastric cancer case study; combined AURKC and CDK6 inhibitors proposed as therapeutic strategy for this patient PMID:25583476
  • High-level copy-number gain in 2 of 29 cutaneous squamous cell carcinoma samples by GISTIC analysis PMID:25589618
  • Recurrently amplified in HNSCC in the 279-tumor TCGA HNSCC cohort (11q13.5 region); co-amplified with CCND1/FADD/CTTN cassette in HPV(-) subset PMID:25631445
  • Mentioned in study PMID:26829750
  • CDK6 amplified in additional ESCCs (especially ESCC2) lacking CCND1 amplification; combined CDKN2A loss and CDK6 amplification in ESCC supports CDK4/6 inhibitor evaluation PMID:28052061
  • Additional recurrently altered candidate driver in medulloblastoma, stratified across subgroups in oncoprint analyses of the ICGC/CBTTC cohort (n=491) PMID:28726821.

Cancer types (linked)

  • Glioblastoma (GB): Identified as a component of the RB signaling pathway, which is altered in approximately 88% of glioblastoma cases PMID:18772890.

Sources

This page was processed by crosslinker on 2026-05-14. - PMID:18948947

This page was processed by crosslinker on 2026-05-14. - PMID:22960745

This page was processed by crosslinker on 2026-05-14. - PMID:23525077

This page was processed by crosslinker on 2026-05-14. - PMID:24120142

This page was processed by crosslinker on 2026-05-14. - PMID:24952746

This page was processed by crosslinker on 2026-05-14. - PMID:25079317

This page was processed by crosslinker on 2026-05-14. - PMID:25583476

This page was processed by crosslinker on 2026-05-14. - PMID:25589618

This page was processed by crosslinker on 2026-05-14. - PMID:25631445

This page was processed by crosslinker on 2026-05-14. - PMID:26829750

This page was processed by wiki-cli on 2026-05-14. - PMID:28052061

This page was processed by wiki-cli on 2026-05-14.

This page was processed by entity-page-writer on 2026-05-15. - PMID:28726821

This page was processed by wiki-cli on 2026-05-15.